D
Black Diamond Therapeutics, Inc. BDTX
$2.56 -$0.13-4.83% NASDAQ
Recommendation
Prev Close
$2.69
Volume
865,791
Avg Vol (90D)
1,083,406
Market Cap
$153.26M
Dividend & Yield
--
52-Week Range
$1.20 - $4.94
P/E (TTM)
7.52
EPS (TTM)
$0.36
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Black Diamond Therapeutics (BDTX) Gets a Buy from Piper Sandler
12/4/2025 - TipRanks Financial Blog
Black Diamond Therapeutics (BDTX): Valuation Check After New Phase 2 Silevertinib Data and Glioblastoma Trial Plans
12/4/2025 - Simply Wall St
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
12/3/2025 - TipRanks Financial Blog
Black Diamond Therapeutics just downgraded at Guggenheim, here's why
12/3/2025 - The Fly
Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim
12/3/2025 - TipRanks Financial Blog
Guggenheim gets more bearish on Black Diamond Therapeutics, downgrades shares
12/3/2025 - The Fly
Black Diamond Reports Promising Phase 2 Lung Cancer Data
12/3/2025 - TipRanks Financial Blog
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and ...
12/3/2025 - GuruFocus
Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Trial Results
12/3/2025 - GuruFocus
Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
12/3/2025 - The Fly
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
12/3/2025 - Globe Newswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 ...
12/2/2025 - GuruFocus
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
12/2/2025 - Globe Newswire
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
11/28/2025 - Zacks Investment Research
Black Diamond Therapeutics (BDTX, $3.81) entered Downtrend as Momentum indicator drops below 0 level on Nov 20, 2025
11/21/2025 - Tickeron - Stocks
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout
11/20/2025 - Seeking Alpha - Long Ideas
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout
11/20/2025 - SeekingAlpha
Piper Sandler Initiates Coverage on Black Diamond Therapeutics (NASDAQ:BDTX)
11/19/2025 - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Piper Sandler
11/19/2025 - Ticker Report
Black Diamond Therapeutics (BDTX, $3.97) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 18, 2025
11/19/2025 - Tickeron - Stocks
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
11/17/2025 - The Fly
What is HC Wainwright's Forecast for BDTX FY2025 Earnings?
11/15/2025 - MarketBeat
Black Diamond Therapeutics (BDTX, $4.49) RSI Indicator left the overbought zone on November 13, 2025
11/14/2025 - Tickeron - Stocks
Black Diamond Therapeutics files $500M mixed securities shelf
11/13/2025 - The Fly
Stifel Nicolaus Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)
11/13/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$70.00M
EBITDA (TTM)
$15.15M
EBIT (TTM)
$14.80M
Net Income (TTM)
$21.50M
Balance Sheet
Total Assets (Q)
$157.73M
Total Debt (Q)
$19.67M
Total Liabilities (Q)
$31.58M
Book Value Per Share (Q)
$2.22
Cash Flow
Cash from Operations (TTM)
$21.35M
Cash from Investing (TTM)
-$14.25M
Cash from Financing (TTM)
$341.00K
Net Change in Cash (TTM)
$7.44M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
2.12
7-Day Total Return
-33.64%
30-Day Total Return
-32.05%
60-Day Total Return
-20.41%
90-Day Total Return
-8.09%
Year to Date Total Return
19.39%
1-Year Total Return
3.86%
2-Year Total Return
8.26%
3-Year Total Return
37.37%
5-Year Total Return
-92.59%
52-week Low
Apr 09, 2025 - $1.20
52-week High
Nov 12, 2025 - $4.94
Valuation
Market Cap
$153.26M - Micro Cap
Enterprise Value
$37.43M
Price/Sales (TTM)
2.19
Price/Book (Q)
1.21
Dividends and Shares
Shares Outstanding
56.93
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.blackdiamondtherapeutics.com
Phone Number
617 252 0848
Address
One Main Street
Cambridge, MA 02142
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s... more
NASDAQ 12/04/2025 10:29AM Eastern Quotes delayed